From BILAG to BLIPS—disease activity assessment in lupus past, present and future.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 651, doi. 10.1191/096120300672904669
- By:
- Publication type:
- Article
Works matching IS 09612033 AND DT 2000 AND VI 9 AND IP 9
Results: 14
1
2
Mytcophenolate mofetil in lupus nephritis.
- Published in:
- 2000
- By:
- Publication type:
- Editorial
3
Immunization with a bacterial ATP-binding cassette transporter fragment suppresses autoimmunity and prolongs survival in MRL/lpr lupus-prone mice.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 655, doi. 10.1191/096120300667608330
- By:
- Publication type:
- Article
4
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 664, doi. 10.1191/096120300674499064
- By:
- Publication type:
- Article
5
Validation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 708, doi. 10.1191/096120300673421268
- By:
- Publication type:
- Article
6
Maculopapular lupus rash in a young woman with systemic involvement.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 713, doi. 10.1191/096120300668126253
- By:
- Publication type:
- Article
7
Wegener's granulomatosis associated with antiphospholipid syndrome.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 717, doi. 10.1191/096120300675018039
- By:
- Publication type:
- Article
8
Vascular events in hypertensive patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 672, doi. 10.1191/096120300669204787
- By:
- Publication type:
- Article
9
The rating scale preference measure as an evaluative measure in systemic lupus erythematosus.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 696, doi. 10.1191/096120300672399292
- By:
- Publication type:
- Article
10
Validation of a Chinese version of the Medical Outcomes Study Family and Marital Functioning Measures in patients with SLE.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 702, doi. 10.1191/096120300666529212
- By:
- Publication type:
- Article
11
Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 676, doi. 10.1191/096120300676096627
- By:
- Publication type:
- Article
12
ASE-1: an autoantigen in systemic lupus erythematosus.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 681, doi. 10.1191/096120300670803230
- By:
- Publication type:
- Article
13
Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 688, doi. 10.1191/096120300677692516
- By:
- Publication type:
- Article
14
SLE, diabetes mellitus and emphysematous infectons of the urinary tract.
- Published in:
- Lupus, 2000, v. 9, n. 9, p. 721, doi. 10.1191/096120300669722665
- By:
- Publication type:
- Article